HydroMg attenuates doxorubicin-induced myocardial injury via promoting mitochondrial function.
Lu Zhang, Yawei Jin, Yuning Zhang, Mohan Li, Xiong Gao, Bin Ma, Xiaonan Ning, Aijun Sun, Wenjiang Ding, Zhiguang Ding, Xiurui Ma, Xiaolei Sun, Jian An · Medical gas research · 2027
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In this animal study, the authors report that In vitro studies showed that 1 μg/mL HydroMg treatment attenuated doxorubicin-induced cardiomyocyte death by inhibiting apoptosis, reducing reactive oxygen species production, and restoring mitochondrial membrane potential.
What the Researchers Studied
Source-reported study description: In contrast to molecular hydrogen's intrinsic limitations, HydroMg's structural optimization shortens gastrointestinal transit, reducing hydrogen dissipation while enhancing cellular bioavailability.
Source-reported study description: However, it remains unclear whether it also provides protection against cardiac injury.
What the Study Found
The authors reported: Here, we investigated the cardioprotective effect of HydroMg, a sustained-release hydrogen donor, against doxorubicin-induced cardiac injury.
What the Findings Mean
The authors concluded/reported: In vitro studies showed that 1 μg/mL HydroMg treatment attenuated doxorubicin-induced cardiomyocyte death by inhibiting apoptosis, reducing reactive oxygen species production, and restoring mitochondrial membrane potential.
Study Details
Publication type: animal_study
Evidence source level: B_ABSTRACT
Original scholarly source: https://pubmed.ncbi.nlm.nih.gov/42734445/